FindTrial
Sign In

Efficacy of Regorafenib Following First-Line Immune Checkpoint Inhibitor Failure in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Study

Efficacy of Regorafenib Following First-Line Immune Checkpoint Inhibitor Failure in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091318
Enrollment
Unknown
Registered
2024-10-25
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Rego group:none
Rego-ICI group:none

Sponsors

the First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: ? Patients with locally advanced or metastatic HCC who are clinically diagnosed or confirmed by histopathology and/or cytology according to the "Diagnosis and Treatment Standards for Primary Liver Cancer" (2021 edition by the Ministry of Health) and are not suitable for surgical resection; ? Failure to receive first-line treatment with PD-1/PD-L1 monoclonal antibodies; ? Second line treatment with regorafenib containing regimen; ? ECOG score = 2 points.

Exclusion criteria

Exclusion criteria: ? Patients with incomplete clinical data; ? Those with incomplete follow-up data.

Design outcomes

Primary

MeasureTime frame
overall survival;—

Secondary

MeasureTime frame
PFS;ORR;DCR;—

Countries

China

Contacts

Public ContactLi Xiangcheng

the First Affiliated Hospital of Nanjing Medical University

drxcli@njmu.edu.cn+86 189 5199 9088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026